GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--LifeVantage Corporation (OTCBB: LFVN), formerly Lifeline Therapeutics, Inc., maker of Protandim®, provided further information regarding human clinical and laboratory studies investigating Protandim®. “We are pleased to report progress on the more than 20 human clinical and laboratory studies involving Protandim®, the unique approach to antioxidant therapy,” said James J. Krejci, Chief Executive Officer of LifeVantage. “Almost all of the studies were initiated as a result of our published, peer-reviewed human clinical trial which demonstrated that Protandim® increased the blood levels of two important antioxidant enzymes while significantly decreasing oxidative stress,” added Krejci.
